



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.	10/661,804	Art Unit:	1636
Applicant:	Schuler <i>et al.</i>	Examiner:	Celine X. Qian
Date Filed:	12 Sept 2003	Conf. No.	8361
Docket No.	1430/16	Cust. No.	25297
Title:	CD4 <sup>+</sup> CD25 <sup>+</sup> Regulatory T Cells from Human Blood		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT C PURSUANT TO 37 C.F.R. §1.116**

Dear Sir:

This is a response to the final Official Action dated November 30, 2006 and in view of the Advisory Action dated March 15, 2007, for which the reply period expires on May 30, 2007. Applicants did not earlier make the amendments to the claims as set forth herein because Applicants sincerely believed that the claims were allowable as previously pending. A Request for Continued Examination (RCE) is being filed simultaneously herewith. Favorable consideration is respectfully requested in view of the following Amendment, Remarks, and RCE.

Amendments of the Claims begin on page 2 of this paper. No new matter has been added.

Remarks/Arguments begin on page 4 of this paper.